Recent Research into the Colon Cancer - Pipeline Review, H2 2016

Colon Cancer - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Complete report available @ Colon Cancer - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Colon Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 35, 3, 155 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 46 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Actinium Pharmaceuticals Inc Adamed Sp z oo Adgero Biopharmaceuticals Inc Advanced Cancer Therapeutics Advanced Proteome Therapeutics Corp Advenchen Laboratories LLC Aeglea BioTherapeutics Inc Affimed GmbH Agenus Inc AGV Discovery SAS AIMM Therapeutics BV Almac Discovery Ltd Ambrx Inc Anavex Life Sciences Corp AndroScience Corp Aphios Corp Aposense Ltd Aptose Biosciences Inc AstraZeneca Plc Aurigene Discovery Technologies Ltd BCN Biosciences LLC Bio-Path Holdings Inc BioCancell Ltd Biogazelle NV Bioncotech Therapeutics SL Blirt SA Boehringer Ingelheim GmbH Can-Fite BioPharma Ltd Celprogen Inc Chiome Bioscience Inc Cyclacel Pharmaceuticals Inc CytomX Therapeutics Inc Cytune Pharma SAS CZ BioMed Corp Daiichi Sankyo Company Ltd DEKK-TEC Inc Eli Lilly and Company EntreChem SL EnzymeBioSystems F. Hoffmann-La Roche Ltd GlaxoSmithKline Plc GlycaNova Norway AS GlycoMimetics Inc Grunenthal GmbH Halozyme Therapeutics Inc Hamlet Pharma AB Hanmi Pharmaceuticals Co Ltd Helix BioPharma Corp Histogen Inc Horizon Pharma Plc Idera Pharmaceuticals Inc Immune Pharmaceuticals Inc Immunome Inc Immunomedics Inc Immunotope Inc Immupharma Plc IMPACT Therapeutics Inc Incuron LLC Infinity Pharmaceuticals Inc Inflection Biosciences Ltd Innopharmax Inc Intezyne Technologies Inc Ironwood Pharmaceuticals Inc Jasco Pharmaceuticals LLC Jiangsu Kanion Pharmaceutical Co Ltd JW Pharmaceutical Corp Karyopharm Therapeutics Inc Kyowa Hakko Kirin Co Ltd Les Laboratoires Servier SAS Lipocure Ltd Lupin Ltd Lymphocyte Activation Technologies SA MabVax Therapeutics Holdings Inc MacroGenics Inc MaxiVAX SA Meabco A/S Medicenna Therapeutics Inc Microlin Bio, Inc. Molecular Targeting Technologies Inc MolMed SpA Monopar Therapeutics LLC Multimmune GmbH NormOxys Inc Northwest Biotherapeutics Inc Novartis AG Omeros Corp Omnitura Therapeutics Inc Oncovir Inc Ono Pharmaceutical Co Ltd Orega Biotech SAS OSE Immunotherapeutics Panacea Pharmaceuticals Inc Patrys Ltd PharmaCyte Biotech Inc Pharminox Ltd Philogen SpA Pique Therapeutics Plexxikon Inc ProNAi Therapeutics Inc Provecs Medical GmbH Provectus Biopharmaceuticals Inc Qu Biologics Inc Recce Pty Ltd Rexahn Pharmaceuticals Inc Rgenix Inc Sareum Holdings Plc Savoy Pharmaceuticals Inc Sellas Inc Sigma-Tau SpA Sirnaomics Inc SOM Biotech SL Somantix BV Sorrento Therapeutics Inc Sphaera Pharma Pvt Ltd Starpharma Holdings Ltd Sunshine Biopharma Inc Synergys Biotherapeutics Inc TaiRx Inc Taiwan Liposome Company Ltd Takis Srl Targovax ASA Transgene Biotek Ltd TVAX Biomedical Inc Tyg Oncology Ltd TyrNovo Ltd Vaccinogen Inc Vault Pharma Inc Vaxenta Biotechnologies Vaximm AG VG Life Sciences Inc Yakult Honsha Co Ltd Zensun (Shanghai) Sci & Tech Co Ltd ZIOPHARM Oncology Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###